Peter Schmid
About
Peter Schmid is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Peter Schmid has authored 198 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 39 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Peter Schmid's work include Cancer Treatment and Pharmacology (40 papers), Advanced Breast Cancer Therapies (28 papers) and Breast Cancer Treatment Studies (26 papers). Peter Schmid is often cited by papers focused on Cancer Treatment and Pharmacology (40 papers), Advanced Breast Cancer Therapies (28 papers) and Breast Cancer Treatment Studies (26 papers). Peter Schmid collaborates with scholars based in Germany, United States and United Kingdom. Peter Schmid's co-authors include Andrew Conrad, Philip Savage, Dave S.�B. Hoon, Kurt Possinger, Javier Cortés, Tilman Steinert, D L Morton, Bernd Flath, K. Possinger and Serge P. von Duvillard and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.
In The Last Decade
Peter Schmid
185 papers receiving 4.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peter Schmid Germany | 38 | 1.9k | 904 | 848 | 732 | 619 | 198 | 4.8k | ||
| Maryam B. Lustberg United States | 40 | 4.0k 2.1× | 953 1.1× | 1.1k 1.3× | 641 0.9× | 365 0.6× | 326 | 6.4k | ||
| Stefan Glück United States | 40 | 3.2k 1.7× | 1.2k 1.3× | 1.1k 1.3× | 1.0k 1.4× | 473 0.8× | 199 | 5.6k | ||
| April Coan United States | 26 | 1.3k 0.7× | 434 0.5× | 655 0.8× | 258 0.4× | 559 0.9× | 38 | 3.0k | ||
| Jesper Frank Christensen Denmark | 40 | 1.4k 0.7× | 4.9k 5.4× | 390 0.5× | 632 0.9× | 598 1.0× | 101 | 8.0k | ||
| Joo‐Hyun Nam South Korea | 41 | 1.2k 0.7× | 1.8k 2.0× | 747 0.9× | 310 0.4× | 324 0.5× | 293 | 7.7k | ||
| Anne Gompel France | 47 | 1.3k 0.7× | 1.2k 1.3× | 326 0.4× | 469 0.6× | 477 0.8× | 189 | 6.5k | ||
| Premal H. Thaker United States | 39 | 1.8k 0.9× | 1.3k 1.4× | 561 0.7× | 570 0.8× | 381 0.6× | 283 | 5.5k | ||
| Shu‐Cheng Chen United States | 40 | 816 0.4× | 1.1k 1.2× | 701 0.8× | 204 0.3× | 1.0k 1.6× | 125 | 6.9k | ||
| Takamasa Kayama Japan | 49 | 829 0.4× | 2.3k 2.5× | 1.4k 1.6× | 698 1.0× | 232 0.4× | 344 | 7.7k | ||
| D. Schrijvers Belgium | 39 | 860 0.5× | 1.6k 1.8× | 605 0.7× | 494 0.7× | 1.7k 2.8× | 133 | 5.4k |
Countries citing papers authored by Peter Schmid
Since
Specialization
Citations
This map shows the geographic impact of Peter Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schmid more than expected).
Fields of papers citing papers by Peter Schmid
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Peter Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schmid. The network helps show where Peter Schmid may publish in the future.
Co-authorship network of co-authors of Peter Schmid
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Schmid. A scholar is included among the top collaborators of Peter Schmid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Schmid. Peter Schmid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Licata, Luca, Giulia Viale, Rebecca Dent, et al.. (2025). Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research. 31(18). 3916–3921.
2.
Pérez-García, José Manuel, Meritxell Bellet, Miguel Gil‐Gil, et al.. (2025). Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. ESMO Open. 10(7). 105309–105309.
3.
Llombart‐Cussac, Antonio, José Manuel Pérez-García, María Gión, et al.. (2024). Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC). Cancer Research. 84(9_Supplement). PO1–20.
4.
Im, Seock‐Ah, Javier Cortés, David W. Cescon, et al.. (2024). Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. npj Breast Cancer. 10(1). 79–79.
5.
Llombart‐Cussac, Antonio, Fara Brasó‐Maristany, Laia Paré, et al.. (2024). HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial. Clinical Cancer Research. 30(18). 4123–4130.
6.
Symeonides, Stefan N., Duncan Wheatley, Stephen Chan, et al.. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment. 199(1). 35–46.
7.
Llombart‐Cussac, Antonio, José Manuel Pérez-García, Peter Schmid, et al.. (2023). 150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial. Annals of Oncology. 34. S240–S241.
8.
Rugo, Hope S., Aditya Bardia, Frederik Marmé, et al.. (2022). Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 40(29). 3365–3376.
9.
Saji, Shigehira, Antonio Llombart‐Cussac, Fabrice André, et al.. (2020). 68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC. Annals of Oncology. 31. S1268–S1268.
10.
Im, S-A., Javier Cortés, Oleg Lipatov, et al.. (2020). 44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation. Annals of Oncology. 31. S1258–S1258.
11.
Rudin, Charles M., Andrés Cervantes, Afshin Dowlati, et al.. (2018). MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S407–S407.
12.
Schmid, Peter. (2017). Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer. European Oncology & Haematology. 13(2). 127–127.
13.
Berent, Robert, Johann Auer, Barry A. Franklin, Peter Schmid, & Serge P. von Duvillard. (2011). Platelet Response to Aspirin 50 and 100 mg in Patients With Coronary Heart Disease Over a Five-Year Period. The American Journal of Cardiology. 108(5). 644–650.
14.
Oguogho, A., et al.. (2010). Prickly pear changes 111indium–LDL and 111indium–HDL platelet binding Correlating to improvement of platelet function in hypercholesterolemia. 12. 67–79.
15.
Kümmel, Sherko, Mahdi Rezai, Rainer Kimmig, & Peter Schmid. (2007). Dose-dense chemotherapy for primary breast cancer. Current Opinion in Obstetrics & Gynecology. 19(1). 75–81.
16.
Steinert, Tilman & Peter Schmid. (2004). Freiwilligkeit und Zwang bei der stationären Behandlung von Patienten mit Schizophrenie. Psychiatrische Praxis. 31(1). 28–33.
17.
Pokan, Rochus, Norbert Bachl, Peter Hofmann, et al.. (2004). Leistungsdiagnostik und Trainingsherzfrequenzbestimmung in der kardiologischen Rehabilitation. Journal für Kardiologie (Krause & Pachernegg GmbH). 11(11). 446–452.
18.
Sarantou, Terry, et al.. (1997). Melanoma-associated antigens as messenger RNA detection markers for melanoma.. PubMed. 57(7). 1371–6.
19.
Schmid, Peter, Peter Itin, David A. Cox, Gary McMaster, & Michel A. Horisberger. (1994). The Type I Interferon System Is Locally Activated in Psoriatic Lesions. Journal of Interferon Research. 14(5). 229–234.
20.
Roeske, William R., et al.. (1978). Alterations in muscarinic cholinergic receptors in transplanted rat hearts. Circulation. 58.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maryam B. Lustberg Breakdown of academic impact, for papers by Stefan Glück Breakdown of academic impact, for papers by April Coan Breakdown of academic impact, for papers by Jesper Frank Christensen Breakdown of academic impact, for papers by Joo‐Hyun Nam Breakdown of academic impact, for papers by Anne Gompel Breakdown of academic impact, for papers by Premal H. Thaker Breakdown of academic impact, for papers by Shu‐Cheng Chen Breakdown of academic impact, for papers by Takamasa Kayama Breakdown of academic impact, for papers by D. Schrijvers